{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:03:19Z","timestamp":1789862599871,"version":"4.0.1"},"reference-count":52,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although the homologous recombination repair (HRR) pathway plays a critical role in the treatment of prostate cancer, its prognostic value remains incompletely understood. This study aimed to identify HRR pathway\u2013related biomarkers with clinical utility for prognosis prediction and treatment guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed genomic data from The Cancer Genome Atlas and Chinese patients with prostate cancer in a retrospective cohort study using a comprehensive multiomics approach to characterize a novel HRR-related prognostic signature and its immune implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the Chinese cohort, 25.6% of the patients exhibited homologous recombination deficiency scores &gt;42, whereas 27.3% carried \u22651 HRR gene mutation. We established a prognostic HRR signature (homologous recombination deficiency score &gt;32, HRR gene mutations, and Signature 3) associated with poor outcomes. Compared with The Cancer Genome Atlas data, the Chinese cohort demonstrated a higher prevalence of HRR signature. Patients with HRR signatures demonstrated significantly increased genomic instability markers, including segment number, alteration burden, aneuploidy score, and intratumor heterogeneity. The HRR signature was associated with higher neoantigen load but reduced T cell receptor (TCR) evenness. Immunologically, HRR-positive tumors were associated with computationally inferred immune profiles suggestive of reduced immune activity, characterized by depletion of T-helper 17 cell; downregulation of\n                      <jats:italic toggle=\"yes\">TLR4<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">PDCD1LG2<\/jats:italic>\n                      expression; and upregulation of\n                      <jats:italic toggle=\"yes\">ARG1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">IFNG<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">KIR2DL3<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">CXCL9<\/jats:italic>\n                      . However, these findings are descriptive and require experimental validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings identify a clinically relevant HRR signature that warrants investigation as a potential predictive biomarker for prostate cancer prognosis and treatment response. This biomarker provides new insights for personalized therapy and may help optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03000605261487253","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:52:17Z","timestamp":1789696337000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value and immune landscape implications of using a novel homologous recombination repair pathway signature in prostate cancer: A retrospective cohort study"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5908-3130","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YE","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MO","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XueLiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuerban","family":"Tuoheti","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QI","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Xinjiang Medical University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00066-5"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020802","article-title":"Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response","volume":"26","author":"Hamid Y","year":"2025","unstructured":"Hamid Y, Rabbani RD, Afsara R, et al. Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response. Int J Mol Sci 2025; 26: 802.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.035"},{"key":"e_1_3_3_6_2","first-page":"280","article-title":"Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors","volume":"4","author":"Zhao D","year":"2024","unstructured":"Zhao D, Wang A, Li Y, et al. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. J Natl Cancer Cent 2024; 4: 280\u2013287.","journal-title":"J Natl Cancer Cent"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189783","article-title":"Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic","volume":"22","author":"Ghose A","year":"2021","unstructured":"Ghose A, Moschetta M, Pappas-Gogos G, et al. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci 2021; 22: 9783.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah S","year":"2021","unstructured":"Shah S, Rachmat R, Enyioma S, et al. BRCA mutations in prostate cancer: assessment, implications and treatment considerations. Int J Mol Sci 2021; 22: 12628.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7740"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad315"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01934-0"},{"key":"e_1_3_3_12_2","article-title":"Utility of homologous recombination deficiency biomarkers across cancer types","volume":"6","author":"Takamatsu S","year":"2022","unstructured":"Takamatsu S, Brown JB, Yamaguchi K, et al. Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis Oncol 2022; 6: e2200085.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13839"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.04.024"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.243"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24788"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts146"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32729"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2135"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.01.220"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-9473(02)00225-6"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32831bc375"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1762473"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14030287","article-title":"The application of radiomics and AI to molecular imaging for prostate cancer","volume":"14","author":"Tapper W","year":"2024","unstructured":"Tapper W, Carneiro G, Mikropoulos C, et al. The application of radiomics and AI to molecular imaging for prostate cancer. J Pers Med 2024; 14: 287.","journal-title":"J Pers Med"},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","unstructured":". Pokorn\u00e1 M \u010cern\u00e1 M Boussios S et al. lncRNA biomarkers of glioblastoma multiforme. Biomedicines 2024; 12. 932.","DOI":"10.3390\/biomedicines12050932"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216863"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2021.03.001"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092249","article-title":"Homologous recombination repair deficiency and implications for tumor immunogenicity","volume":"13","author":"van Wilpe S","year":"2021","unstructured":"van Wilpe S, Tolmeijer SH, Koornstra RHT, et al. Homologous recombination repair deficiency and implications for tumor immunogenicity. Cancers (Basel) 2021; 13: 2249.","journal-title":"Cancers (Basel)"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01678-x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01283-7"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00561"},{"key":"e_1_3_3_35_2","article-title":"Pretreatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy","author":"Casarrubios M","unstructured":"Casarrubios M, Cruz-Berm\u00fadez A, Nadal E, et al. Pretreatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Clin Cancer Res 2021; 27: 5878\u20135890.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0136"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202267"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.02.011"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-019-01146-9"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.10.015"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2109865"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmaa116"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.03.012"},{"key":"e_1_3_3_44_2","article-title":"Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression","volume":"8","author":"Wang F","year":"2013","unstructured":"Wang F, Xu J, Zhu Q, et al. Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression. PLOS One 2013; 8: e79064.","journal-title":"PLOS One"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3963"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1980"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010079","article-title":"Melanoma cell resistance to vemurafenib modifies inter-cellular communication signals","volume":"9","author":"Tabolacci C","year":"2021","unstructured":"Tabolacci C, Cordella M, Mariotti S, et al. Melanoma cell resistance to vemurafenib modifies inter-cellular communication signals. Biomedicines 2021; 9: 79.","journal-title":"Biomedicines"},{"key":"e_1_3_3_48_2","first-page":"1305","article-title":"CXCL9 Promotes prostate cancer progression through inhibition of cytokines from T cells","volume":"18","author":"Tan S","year":"2018","unstructured":"Tan S, Wang K, Sun F, et al. CXCL9 Promotes prostate cancer progression through inhibition of cytokines from T cells. Mol Med Rep 2018; 18: 1305\u20131310.","journal-title":"Mol Med Rep"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13413"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13486"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79419-3"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27041797","article-title":"PD-L1 expression in prostate cancer: anatomopathological features, methodological pitfalls, and therapeutic potential","volume":"27","author":"Pepe L","year":"2026","unstructured":"Pepe L, Pizzimenti C, Tralongo P, et al. PD-L1 expression in prostate cancer: anatomopathological features, methodological pitfalls, and therapeutic potential. Int J Mol Sci 2026; 27: 1797.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19548-y"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261487253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261487253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261487253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:18:27Z","timestamp":1789859907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261487253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/03000605261487253"],"URL":"https:\/\/doi.org\/10.1177\/03000605261487253","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"03000605261487253"}}